Pierre De Oliveira

Product Exclusivity Strategies

• Advised public and private companies on the creation and expansion of regulatory and patent exclusivity strategies to protect therapeutic products
• Formulated and deployed patent and regulatory strategies to maximize exclusivity for repurposed and repositioned drugs products

Patent Prosecution and Strategic Counseling

• Advised public commercial-stage regenerative medicine company on extending patent protection for its commercialized product
• Advised a private company focused on licensing, developing and commercializing antidotes for a variety of poisons
• Advised a private pharmaceutical company developing breakthrough therapies for urogenital conditions
• Advised a public drug discovery company developing small molecule therapies for neurological diseases
• Advised a private biopharmaceutical company with multiple, ongoing late-stage clinical development programs in neurosciences and dementia, rare diseases, dermatology and endocrinology
• Advised a private drug discovery company focused on the development of small molecule drugs capable of modulating protein stability
• Advised a biopharmaceutical company focused on the development of peptide-based therapeutics for the treatment of ocular disorders
• Advised a specialty pharmaceutical company focused on the development of therapeutics for neonatal and pediatric patients
• Advised multinational pharmaceutical company on patent preparation and prosecution of patents for pre-clinical oncology products

IP Due Diligence and Transactions

• Conducted IP due diligence in support of licensing efforts for public and private biotechnology companies
• Served as IP counsel for clinical-stage biopharmaceutical company in its US$45.2 million initial public offering
• Served as IP counsel for a commercial-stage regenerative medicine company in its US$50 million initial public offering
• Advised private biopharmaceutical company, conducting IP due diligence in support of strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies to augment its late-stage clinical development programs in neurosciences and dementia
• Advised a private early-stage drug discovery and development company in negotiating collaboration and license agreement with a global pharmaceutical company involving US$6 million in upfront payments and US$64 million in potential milestone payments
• Conducted internal IP due diligence reviews and audits on behalf of pharmaceutical, biopharmaceutical and medical device companies in preparation for partnering, financing and public offerings
• Provided counsel on and prepared nondisclosure agreements, consulting agreements, license agreements and collaboration/joint venture agreements for biotechnology companies

The Legal 500 United States

• Recommended, Patents: Prosecution (including re-examination and post-grant proceedings), (2025)

Additional Recognitions

• Ones to Watch, Intellectual Property Law, Best Lawyers in America, (2024 – 2025)
• Ones to Watch, Patent Law, Best Lawyers in America, (2024 – 2025)
• Ones to Watch, Life Sciences Practice, Best Lawyers in America, (2023 – 2025)
• Recipient, Student Leadership Award, Pittsburgh Intellectual Property Association, (2014)
• Recipient, CALI Award for Excellent Achievement in the Study of Commercial Use of Intellectual Property, (2013)

• Co-author, "Federal Circuit denies Cellect’s en banc petition, maintaining impact of obviousness-type double-patenting on patent term adjustment," Intellectual Property News, March 7, 2024
• Co-author, "Aligning A Product's Marketing, Regulatory and IP Plans," Law360, September 8, 2017
• Co-author, "Supreme Court Affords Greater Leeway to Biosimilars in the 'Patent Dance'," Pepper Hamilton LLP Client Alert, June 2017
• Co-author, "Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis," Journal of Surgical Research, December 2011
• Co-author, "Cytoplasmic Overexpression of CD95L in esophageal Adenocarcinoma Cells Overcomes Resistance to CD95-Mediated Apoptosis," Science Direct, March 2011
• Co-author, "Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21," PubMed, October 2009
• Co-author, "Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages," PubMed, September 2009
• Co-author, "Is a step backwards in S-phase-targeted chemotherapy a step forward?" PubMed, June 2008
• Co-author, "Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer," PubMed, September 2007
• Co-author, "Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma," PubMed, November 2006
• Co-author, "Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1," PubMed, August 2006
• Co-author, "Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma," PubMed, January 2006
• Co-author, "Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma," Journal of Surgical Research, February 2005
• Co-author, "The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma," PubMed, January 2005